Blockade of tumour necrosis factor α significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis

Yazdani‐Biuki, Babak; Stadlmaier, E.; A, Mulabecirovic; Brezinschek, Ruth I.; Tilz, G. P.; Demel, Ulrike; Mueller, Thomas; Brickmann, Kerstin; Graninger, Winfried; Brezinschek, Hans‐Peter

doi:10.1136/ard.2004.030262

Cited by 35 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it is tempting to categorize IgM RFs as beneficial or innocuous and IgG and IgA RFs as detrimental, the case is not as straightforward as it may appear. A recent study on 12 seropositive RA patients indicated that IgG and IgA RFs actually increase as patients respond to anti-TNFα therapy [68]. Since IgG and IgA RFs are not routinely measured in the clinic there is much less known about them and it will be critical to conduct further studies to determine their importance in chronic disease.…”

Section: Resultsmentioning

confidence: 99%

Rheumatoid Factors: Good or Bad for You?

Nowak

Newkirk

2005

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Rheumatoid factors (RFs) are autoantibodies associated with rheumatoid arthritis. They can be detected in normal individuals, although transiently. This dichotomy has led to questions about the origins and types of RFs. Recently it has been shown that B cells that produce RFs only do so when activated by two signals, one from engagement of the B-cell receptor and the other from recognition of a pathogen-associated molecular pattern through a Toll-like receptor (TLR). These autoantibodies thus link the innate and acquired immune responses. Objective: Through a review of the literature, an examination of the current knowledge of RF induction is presented. The focus is on a discussion of a beneficial or detrimental role for RFs in normal individuals and in those with chronic disease. Results: What makes RF ‘good’ in some cases and ‘bad’ in others may reflect the type of RF produced. Low-affinity polyreactive IgM RFs are probably beneficial as they aid in the clearance of immune complexes that are more efficiently cleared, and the RF B cell can act as an antigen-presenting cell and stimulate host defense. However, large amounts of high-affinity RFs found in patients with chronic disease may be harmful by participation in a vicious cycle of autoantibody production by stimulation of self lymphocytes, and/or deposition in blood vessels thus causing vasculitis. Conclusions: Whether RFs are beneficial or detrimental depends on the context in which they are expressed, the type and amount of RF produced, whether the response is perpetuated by TLR ligation and whether other cells are stimulated either directly or indirectly by RF-positive B cells.

show abstract

Section: Resultsmentioning

confidence: 99%

Rheumatoid Factors: Good or Bad for You?

Nowak

Newkirk

2005

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Andrographolide can reduce the TNFα production in macrophages, an effect that could be associated with the reduction of auto-antibodies. It is known that a reduction of TNFα can diminish significantly the RF levels [86]. The ability of andrographolide to reduce antibody titer has also been demonstrated in other autoimmune diseases such as experimental autoimmune encephalomyelitis and lupus (see above).…”

Section: Efficacy Of An Andrographis Paniculata Composition (Paractinmentioning

confidence: 93%

Andrographolide a New Potential Drug for the Long Term Treatment of Rheumatoid Arthritis Disease

Hidalgo¹,

Hancke²,

Bertoglio³

et al. 2013

Innovative Rheumatology

View full text Add to dashboard Cite

“…Thus, several reports indicated increased production of SLE-specific autoantibodies [18,19]. Moreover, we have recently demonstrated that therapy with etanercept, but not with adalimumab significantly increased the amount of RF-IgG and -IgA [20].…”

Section: The Next Step: Biologic Response Modifiers (Brm)mentioning

confidence: 95%

Behandlung der Rheumatoiden Arthritis im 21. Jahrhundert: Gegen B-Zellen gerichtete Therapien

Brezinschek

Brickmann

Yazdani‐Biuki

et al. 2006

Wien Med Wochenschr

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent inflammation of synovial tissue. Although the initiating event of RA is still unknown, recent research has demonstrated the importance of the increased production of tumor necrosis factor (TNF) alpha in the perpetuation of the inflammatory process of this disease. Targeting this molecule with soluble receptors, i.e., etanercept, or antibodies, like infliximab or adalimumab, a new class of highly effective anti rheumatic drugs has been developed. Unfortunately, not all patients respond sufficiently to TNF blockade and some of the patients become unresponsive to TNF-blocking agents. Targeting B-lymphocytes in these patients has opened a new therapeutic window. It has been demonstrated that B-lymphocytes have an important impact in the pathophysiology of RA. These cells produce not only a variety of autoantibodies, but directly stimulate autoaggressive T lymphocytes in the synovium. Furthermore, B-lymphocytes produce a variety of proinflammatory cytokines that also activate monocytes and synoviocytes. Several placebo-controlled clinical trials have demonstrated the efficacy of B-lymphocyte-directed therapy in patients that have responded poorly to conventional disease-modifying drugs or TNF blockade. In addition, several other B-cell specific antigens are potential targets in different autoimmune diseases.

show abstract

Blockade of tumour necrosis factor α significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis

Cited by 35 publications

References 14 publications

Rheumatoid Factors: Good or Bad for You?

Rheumatoid Factors: Good or Bad for You?

Andrographolide a New Potential Drug for the Long Term Treatment of Rheumatoid Arthritis Disease

Behandlung der Rheumatoiden Arthritis im 21. Jahrhundert: Gegen B-Zellen gerichtete Therapien

Contact Info

Product

Resources

About